Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000995 | 0.75 | CA1 (0.44) | CA1CA2EGFRLMNAKMT2A | |
| SCHEMBL27631115 | 0.75 | POLB (0.38) | SMN1; SMN2LMNAHTTALDH1A1PKM | |
| SCHEMBL25129257 | 0.75 | ALDH1A1 (0.44) | SMN1; SMN2L3MBTL1LMNAALDH1A1PKM | |
| SCHEMBL25754551 | 0.75 | NSD2 (0.44) | SMN1; SMN2NPC1RAB9AL3MBTL1LMNA | |
| SCHEMBL25537296 | 0.75 | KMT2A (0.39) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL31206017 | 0.73 | CA12 (0.41) | FTOSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL2201120 | 0.73 | FTO (0.50) | FTOSMN1; SMN2NPC1RAB9ACA12 | |
| SCHEMBL762825 | 0.73 | L3MBTL1 (0.56) | FTOSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL29706147 | 0.73 | L3MBTL1 (0.56) | FTOSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL5379893 | 0.72 | FTO (0.38) | FTOSMN1; SMN2NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993590-B2 | Pyranone compounds useful to modulate OMA1 protease | 712 NORTH INC. (US) | 2024-05-28 | — | — | US | claimed |
| WO-2023154528-A1 | STEREOSELECTIVE TECHNOLOGIES FOR CHIRAL COMPOUNDS | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021237223-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2020073011-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| CN-107250135-A | The preparation method of long-acting dipeptidy peptidase in inhibitors, purposes and its intermediate | 四川科伦药物研究院有限公司 | 2017-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993590-B2 | Pyranone compounds useful to modulate OMA1 protease | OPA1, OLA1, PITRM1 | FTO 3076/4885SMN1; SMN2 1815/4885NPC1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.